Pub Date : 2025-11-25DOI: 10.1038/s41409-025-02763-3
Jaime Sanz, Allain-Thibeault Ferhat, Anna Maria Raiola, Didier Blaise, Mutlu Arat, Yener Koc, Malek Benakli, Mi Kwon, Alexander Kulagin, Matteo Parma, Simona Sica, Johanna Tischer, Jiri Pavlu, Nathalie Dhedin, Giovanni Grillo, Nicolaus Kröger, Juan Montoro, Sebastian Giebel, Zina Peric, Bipin Savani, Arnon Nagler, Simona Piemontese, Mohamad Mohty, Fabio Ciceri
Haploidentical hematopoietic cell transplantation (HCT) is widely used in high-risk acute lymphoblastic leukemia (ALL), yet optimal donor selection remains unclear. We retrospectively analyzed 933 ALL patients receiving post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis to evaluate the impact of donor characteristics on outcomes. Donors had a median age of 36 years; 38% were female, including 23% who donated to male recipients. Peripheral blood (PB) was the graft source in 69%, and CMV-seronegative donors were used in 16% of CMV-negative recipients. Multivariate analysis showed that PB grafts were associated with inferior overall survival (OS) and GVHD-free/relapse-free survival. CMV-matched seronegative pairs had reduced non-relapse mortality and improved OS. Chronic GVHD was more frequent with older donors and in male recipients of female donor grafts, the latter also increasing extensive cGVHD risk. In conclusion, donor and graft selection significantly influence outcomes after haplo-HCT with PTCy. When feasible, bone marrow should be favored over PB grafts, and CMV-seronegative donors prioritized for CMV-seronegative recipients. Older donor age and female-to-male sex mismatch were associated with increased chronic GVHD risk.
{"title":"Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT","authors":"Jaime Sanz, Allain-Thibeault Ferhat, Anna Maria Raiola, Didier Blaise, Mutlu Arat, Yener Koc, Malek Benakli, Mi Kwon, Alexander Kulagin, Matteo Parma, Simona Sica, Johanna Tischer, Jiri Pavlu, Nathalie Dhedin, Giovanni Grillo, Nicolaus Kröger, Juan Montoro, Sebastian Giebel, Zina Peric, Bipin Savani, Arnon Nagler, Simona Piemontese, Mohamad Mohty, Fabio Ciceri","doi":"10.1038/s41409-025-02763-3","DOIUrl":"10.1038/s41409-025-02763-3","url":null,"abstract":"Haploidentical hematopoietic cell transplantation (HCT) is widely used in high-risk acute lymphoblastic leukemia (ALL), yet optimal donor selection remains unclear. We retrospectively analyzed 933 ALL patients receiving post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis to evaluate the impact of donor characteristics on outcomes. Donors had a median age of 36 years; 38% were female, including 23% who donated to male recipients. Peripheral blood (PB) was the graft source in 69%, and CMV-seronegative donors were used in 16% of CMV-negative recipients. Multivariate analysis showed that PB grafts were associated with inferior overall survival (OS) and GVHD-free/relapse-free survival. CMV-matched seronegative pairs had reduced non-relapse mortality and improved OS. Chronic GVHD was more frequent with older donors and in male recipients of female donor grafts, the latter also increasing extensive cGVHD risk. In conclusion, donor and graft selection significantly influence outcomes after haplo-HCT with PTCy. When feasible, bone marrow should be favored over PB grafts, and CMV-seronegative donors prioritized for CMV-seronegative recipients. Older donor age and female-to-male sex mismatch were associated with increased chronic GVHD risk.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 2","pages":"166-171"},"PeriodicalIF":5.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145602210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.1038/s41409-025-02757-1
Rasha W. Al-Ali, Gege Gui, Niveditha Ravindra, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong, Ying Huang, Jason Gerhold, Matt Holman, Austin Jacobsen, Julian D’Angelo, Jeffrey Miller, Karina Elias, Jeffery J. Auletta, Firas El Chaer, Steven M. Devine, Antonio Martin Jimenez Jimenez, Marcos J. G. De Lima, Mark R. Litzow, Partow Kebriaei, Wael Saber, Stephen R. Spellman, Scott L. Zeger, Kristin M. Page, Jerald P. Radich, R. Coleman Lindsley, Laura W. Dillon, Christopher S. Hourigan
{"title":"Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia","authors":"Rasha W. Al-Ali, Gege Gui, Niveditha Ravindra, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong, Ying Huang, Jason Gerhold, Matt Holman, Austin Jacobsen, Julian D’Angelo, Jeffrey Miller, Karina Elias, Jeffery J. Auletta, Firas El Chaer, Steven M. Devine, Antonio Martin Jimenez Jimenez, Marcos J. G. De Lima, Mark R. Litzow, Partow Kebriaei, Wael Saber, Stephen R. Spellman, Scott L. Zeger, Kristin M. Page, Jerald P. Radich, R. Coleman Lindsley, Laura W. Dillon, Christopher S. Hourigan","doi":"10.1038/s41409-025-02757-1","DOIUrl":"10.1038/s41409-025-02757-1","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 2","pages":"222-224"},"PeriodicalIF":5.2,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02757-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-22DOI: 10.1038/s41409-025-02767-z
John A. Snowden, Vivak Parkash, Nina Knelange, Jan Styczynski, Gloria Tridello, Thushan de Silva, Dietger Niederwieser, Mahmoud Aljurf, Anna Sureda, Malgorzata Mikulska, Rafael de la Camara, Dina Averbuch
{"title":"Neglected tropical diseases (NTDs) and related infections in hematopoietic cellular therapy (HCT) in adults and children: a survey from the Infectious Diseases Working Party (IDWP) of the European Society of Blood and Marrow Transplantation (EBMT)","authors":"John A. Snowden, Vivak Parkash, Nina Knelange, Jan Styczynski, Gloria Tridello, Thushan de Silva, Dietger Niederwieser, Mahmoud Aljurf, Anna Sureda, Malgorzata Mikulska, Rafael de la Camara, Dina Averbuch","doi":"10.1038/s41409-025-02767-z","DOIUrl":"10.1038/s41409-025-02767-z","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 2","pages":"219-221"},"PeriodicalIF":5.2,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-21DOI: 10.1038/s41409-025-02740-w
Kordelia Barbullushi, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Arnold Ganser, Wolfgang Bethge, Hermann Einsele, Johannes Schetelig, Renato Fanin, Pavel Jindra, Thomas Schroeder, Jochen Casper, Matthias Edinger, Jakob Passweg, Edouard Forcade, Johanna Tischer, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Primary refractory acute myeloid leukemia (prAML) is a poor prognosis disease, with allogeneic hematopoietic stem cell transplantation (allo-HSCT) being the only potentially curative option. We retrospectively evaluated outcomes in 1574 adult prAML patients who underwent allo-HSCT from matched sibling donors (MSD), 10/10 or 9/10 unrelated donors (UD), or haploidentical donors between 2015 and 2020. Median follow-up was 24, 30, 38, and 24 months for MSD, UD 10/10, UD 9/10, and haploidentical transplants, respectively. MSD recipients were younger (median age 53 vs. 58–59 years in other groups, p < 0.001), had better performance status, and proceeded to transplant more quickly (3.8 months vs. >4 months in other groups, p = 0.004). In multivariate analysis, haploidentical HSCT was associated with inferior leukemia-free survival (LFS) and overall survival (OS) compared to other donor types. Additional negative predictors included adverse cytogenetics and longer time from diagnosis to transplant. Conversely, reduced-intensity conditioning and good performance status of the patient were associated with improved LFS. Disease progression remained the leading cause of transplant failure, underscoring the urgent need for more effective early post-transplant strategies.
{"title":"Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT","authors":"Kordelia Barbullushi, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Arnold Ganser, Wolfgang Bethge, Hermann Einsele, Johannes Schetelig, Renato Fanin, Pavel Jindra, Thomas Schroeder, Jochen Casper, Matthias Edinger, Jakob Passweg, Edouard Forcade, Johanna Tischer, Arnon Nagler, Fabio Ciceri, Mohamad Mohty","doi":"10.1038/s41409-025-02740-w","DOIUrl":"10.1038/s41409-025-02740-w","url":null,"abstract":"Primary refractory acute myeloid leukemia (prAML) is a poor prognosis disease, with allogeneic hematopoietic stem cell transplantation (allo-HSCT) being the only potentially curative option. We retrospectively evaluated outcomes in 1574 adult prAML patients who underwent allo-HSCT from matched sibling donors (MSD), 10/10 or 9/10 unrelated donors (UD), or haploidentical donors between 2015 and 2020. Median follow-up was 24, 30, 38, and 24 months for MSD, UD 10/10, UD 9/10, and haploidentical transplants, respectively. MSD recipients were younger (median age 53 vs. 58–59 years in other groups, p < 0.001), had better performance status, and proceeded to transplant more quickly (3.8 months vs. >4 months in other groups, p = 0.004). In multivariate analysis, haploidentical HSCT was associated with inferior leukemia-free survival (LFS) and overall survival (OS) compared to other donor types. Additional negative predictors included adverse cytogenetics and longer time from diagnosis to transplant. Conversely, reduced-intensity conditioning and good performance status of the patient were associated with improved LFS. Disease progression remained the leading cause of transplant failure, underscoring the urgent need for more effective early post-transplant strategies.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 2","pages":"149-158"},"PeriodicalIF":5.2,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-18DOI: 10.1038/s41409-025-02738-4
Amandeep Salhotra, Dongyun Yang, Monzr M. Al Malki, Sally Mokhtari, Diana Knobler, Vaibhav Agarwal, Karamjeet Sandhu, Gabriel Park, Ahmed Aribi, Haris Ali, Ibrahim Aldoss, Salman Otoukesh, Shukaib Arslan, Brian Ball, Paul Koller, Idoroenyi Amanam, Hoda Pourhassan, Amanda Blackmon, Pamela Becker, Vinod Pullarkat, Andrew S. Artz, Eileen Smith, Guido Marcucci, Stephen Forman, Anthony Stein, Ryotaro Nakamura
Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly offered as a consolidation strategy for older/infirm patients with acute myeloid leukemia (AML). Fludarabine/melphalan (Flu/Mel) conditioning is associated with effective disease control but results in significant toxicity and non-relapse mortality (NRM) when combined with calcineurin-inhibitors plus methotrexate or mycophenolate mofetil. Flu/Mel with alternative graft-versus-host disease (GVHD) prophylaxis may be better tolerated and result in superior outcomes in patients with AML. In this single-center retrospective analysis, we analyzed long-term outcomes of patients with AML (n = 342) who underwent allo-HCT with Flu/Mel conditioning and tacrolimus/sirolimus (Tac/Sir)-based GVHD prophylaxis from 2008-2019 at City of Hope. Patient median age was 63 years (range: 23–78), with 37% having high-very high Disease Risk Index (DRI) and 42% with HCT-Comorbidity Index (CI) ≥ 3. Five-year overall survival (OS: primary objective) was 55% (95% CI: 49–61%) among all patients and 70% (95% CI: 55–81%) in patients ≥70 years old. Only presence of active disease correlated with lower 5-year OS on multivariate analysis (HR = 1.95; p < .001). Five-year NRM was 24% (95% CI: 19–29%) among all patients and 21% (95% CI: 11–34%) in those ≥70 years old. In conclusion, Flu/Mel conditioning with Tac/Sir GVHD prophylaxis is associated with favorable OS and acceptable NRM, even in older/infirm patients with AML.
{"title":"Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis","authors":"Amandeep Salhotra, Dongyun Yang, Monzr M. Al Malki, Sally Mokhtari, Diana Knobler, Vaibhav Agarwal, Karamjeet Sandhu, Gabriel Park, Ahmed Aribi, Haris Ali, Ibrahim Aldoss, Salman Otoukesh, Shukaib Arslan, Brian Ball, Paul Koller, Idoroenyi Amanam, Hoda Pourhassan, Amanda Blackmon, Pamela Becker, Vinod Pullarkat, Andrew S. Artz, Eileen Smith, Guido Marcucci, Stephen Forman, Anthony Stein, Ryotaro Nakamura","doi":"10.1038/s41409-025-02738-4","DOIUrl":"10.1038/s41409-025-02738-4","url":null,"abstract":"Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly offered as a consolidation strategy for older/infirm patients with acute myeloid leukemia (AML). Fludarabine/melphalan (Flu/Mel) conditioning is associated with effective disease control but results in significant toxicity and non-relapse mortality (NRM) when combined with calcineurin-inhibitors plus methotrexate or mycophenolate mofetil. Flu/Mel with alternative graft-versus-host disease (GVHD) prophylaxis may be better tolerated and result in superior outcomes in patients with AML. In this single-center retrospective analysis, we analyzed long-term outcomes of patients with AML (n = 342) who underwent allo-HCT with Flu/Mel conditioning and tacrolimus/sirolimus (Tac/Sir)-based GVHD prophylaxis from 2008-2019 at City of Hope. Patient median age was 63 years (range: 23–78), with 37% having high-very high Disease Risk Index (DRI) and 42% with HCT-Comorbidity Index (CI) ≥ 3. Five-year overall survival (OS: primary objective) was 55% (95% CI: 49–61%) among all patients and 70% (95% CI: 55–81%) in patients ≥70 years old. Only presence of active disease correlated with lower 5-year OS on multivariate analysis (HR = 1.95; p < .001). Five-year NRM was 24% (95% CI: 19–29%) among all patients and 21% (95% CI: 11–34%) in those ≥70 years old. In conclusion, Flu/Mel conditioning with Tac/Sir GVHD prophylaxis is associated with favorable OS and acceptable NRM, even in older/infirm patients with AML.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"82-91"},"PeriodicalIF":5.2,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02738-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-18DOI: 10.1038/s41409-025-02745-5
Magdalena Corona, Samantha Brown, Kai Rejeski, Jessica R. Flynn, Sean M. Devlin, Sandeep Raj, Alejandro Luna de Abia, Richard J. Lin, Michael Scordo, Gunjan L. Shah, M. Lia Palomba, Alexander P. Boardman, Lorenzo Falchi, Jennifer Lue, Gilles Salles, Jae Park, Sergio A. Giralt, Miguel-Angel Perales, Roni Shouval, Parastoo B. Dahi
Late Immune Effector Cell-Associated HematoToxicity (ICAHT) is a recognized complication following CAR T therapy, yet their incidence and clinical consequences remain poorly defined. We assessed early and late hematotoxicity in 290 patients with large B-cell lymphoma receiving CAR T therapy. Early ICAHT ( ≤ 30 days post-infusion) occurred in 78% of patients (grade 1: 22%, grade 2: 26%, grade 3: 22%, grade 4: 8.1%). Cumulative incidence of late ICAHT ( > 30 days post-infusion) by day 100 was 45% (95% CI 39–51) for any grade, 40% (95% CI 34-46) for grade≥2, 22% (95% CI 17–27) for grade ≥3, and 7.2% (95% CI 4.4–11) for grade 4. Cumulative incidences of late moderate-severe thrombocytopenia ( < 50 × 103/μL) and anemia ( < 8 g/dL) at day 100 were 20% (95% CI 15–25) and 14% (95% CI 10-19), respectively. Early severe ICAHT (grade ≥3) was independently associated with late severe ICAHT (p < 0.001), late severe thrombocytopenia (p < 0.001), and late moderate-severe anemia (p = 0.037). Late severe ICAHT was associated with an increased hazard of late infections (HR 2.85 [95% CI 1.18–6.88], p = 0.032). These findings highlight late hematologic toxicity as a frequent and clinically relevant complication of CAR T therapy. Incorporating ICAHT grading into post-infusion monitoring may inform preventive strategies to mitigate long-term complications.
晚期免疫效应细胞相关血液毒性（ICAHT）是CAR - T治疗后公认的并发症，但其发病率和临床后果仍不明确。我们评估了290例接受CAR - T治疗的大b细胞淋巴瘤患者的早期和晚期血液毒性。78%的患者出现早期ICAHT（输注后≤30天）（1级：22%，2级：26%，3级：22%，4级：8.1%）。到第100天，任何级别的晚期ICAHT累积发生率为45% (95% CI 39-51)，≥2级为40% (95% CI 34-46)，≥3级为22% (95% CI 17-27)， 4级为7.2% （95% CI 4.4-11）。中重度血小板减少症（3/μL）和贫血(
{"title":"Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact","authors":"Magdalena Corona, Samantha Brown, Kai Rejeski, Jessica R. Flynn, Sean M. Devlin, Sandeep Raj, Alejandro Luna de Abia, Richard J. Lin, Michael Scordo, Gunjan L. Shah, M. Lia Palomba, Alexander P. Boardman, Lorenzo Falchi, Jennifer Lue, Gilles Salles, Jae Park, Sergio A. Giralt, Miguel-Angel Perales, Roni Shouval, Parastoo B. Dahi","doi":"10.1038/s41409-025-02745-5","DOIUrl":"10.1038/s41409-025-02745-5","url":null,"abstract":"Late Immune Effector Cell-Associated HematoToxicity (ICAHT) is a recognized complication following CAR T therapy, yet their incidence and clinical consequences remain poorly defined. We assessed early and late hematotoxicity in 290 patients with large B-cell lymphoma receiving CAR T therapy. Early ICAHT ( ≤ 30 days post-infusion) occurred in 78% of patients (grade 1: 22%, grade 2: 26%, grade 3: 22%, grade 4: 8.1%). Cumulative incidence of late ICAHT ( > 30 days post-infusion) by day 100 was 45% (95% CI 39–51) for any grade, 40% (95% CI 34-46) for grade≥2, 22% (95% CI 17–27) for grade ≥3, and 7.2% (95% CI 4.4–11) for grade 4. Cumulative incidences of late moderate-severe thrombocytopenia ( < 50 × 103/μL) and anemia ( < 8 g/dL) at day 100 were 20% (95% CI 15–25) and 14% (95% CI 10-19), respectively. Early severe ICAHT (grade ≥3) was independently associated with late severe ICAHT (p < 0.001), late severe thrombocytopenia (p < 0.001), and late moderate-severe anemia (p = 0.037). Late severe ICAHT was associated with an increased hazard of late infections (HR 2.85 [95% CI 1.18–6.88], p = 0.032). These findings highlight late hematologic toxicity as a frequent and clinically relevant complication of CAR T therapy. Incorporating ICAHT grading into post-infusion monitoring may inform preventive strategies to mitigate long-term complications.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 2","pages":"142-148"},"PeriodicalIF":5.2,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02745-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-18DOI: 10.1038/s41409-025-02768-y
Lorenzo Lazzari, Aitana Balaguer-Roselló, Alessandro Bruno, Juan Montoro, Raffaella Greco, Pedro Chorao, Maria Teresa Lupo-Stanghellini, Marta Villalba, Simona Piemontese, Andrea Assanelli, Miguel A. Sanz, Jacopo Peccatori, Annalisa Ruggeri, Fabio Ciceri, Jaime Sanz
{"title":"Impact of busulfan- versus treosulfan-based conditioning on the incidence of sinusoidal obstruction syndrome/veno-occlusive disease after allogeneic hematopoietic cell transplantation: a dual-center real-world study","authors":"Lorenzo Lazzari, Aitana Balaguer-Roselló, Alessandro Bruno, Juan Montoro, Raffaella Greco, Pedro Chorao, Maria Teresa Lupo-Stanghellini, Marta Villalba, Simona Piemontese, Andrea Assanelli, Miguel A. Sanz, Jacopo Peccatori, Annalisa Ruggeri, Fabio Ciceri, Jaime Sanz","doi":"10.1038/s41409-025-02768-y","DOIUrl":"10.1038/s41409-025-02768-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"118-120"},"PeriodicalIF":5.2,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Outcomes of hematopoietic stem cell transplantation for patients with monomorphic epitheliotropic intestinal T-cell lymphoma: retrospective study from the Adult Lymphoma Working Group of the Japan Society for Transplantation and Cellular Therapy","authors":"Kodai Kuriyama, Mizuki Watanabe, Takeshi Okatani, Shuichi Ota, Hiroyuki Takahashi, Kohmei Kubo, Hideyuki Nakazawa, Kazutaka Ozeki, Junya Kanda, Toshiyuki Kitano, Nobuhiro Hiramoto, Yasufumi Uehara, Yasuhiko Miyazaki, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Eisei Kondo","doi":"10.1038/s41409-025-02752-6","DOIUrl":"10.1038/s41409-025-02752-6","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"110-113"},"PeriodicalIF":5.2,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：